X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Lupin Ltd with Novartis - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN LTD vs NOVARTIS - Comparison Results

LUPIN LTD    Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN LTD NOVARTIS LUPIN LTD/
NOVARTIS
 
P/E (TTM) x 22.8 393.4 5.8% View Chart
P/BV x 3.1 19.4 15.9% View Chart
Dividend Yield % 0.8 1.5 54.5%  

Financials

 LUPIN LTD   NOVARTIS
EQUITY SHARE DATA
    LUPIN LTD
Mar-17
NOVARTIS
Mar-16
LUPIN LTD/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs1,750982 178.2%   
Low Rs1,384556 248.7%   
Sales per share (Unadj.) Rs387.4252.9 153.2%  
Earnings per share (Unadj.) Rs56.662.1 91.1%  
Cash flow per share (Unadj.) Rs76.863.3 121.4%  
Dividends per share (Unadj.) Rs7.5010.00 75.0%  
Dividend yield (eoy) %0.51.3 36.8%  
Book value per share (Unadj.) Rs298.9363.6 82.2%  
Shares outstanding (eoy) m451.5831.96 1,413.0%   
Bonus/Rights/Conversions ESOPS--  
Price / Sales ratio x4.03.0 133.0%   
Avg P/E ratio x27.712.4 223.5%  
P/CF ratio (eoy) x20.412.2 167.8%  
Price / Book Value ratio x5.22.1 247.8%  
Dividend payout %13.216.1 82.3%   
Avg Mkt Cap Rs m707,51324,580 2,878.4%   
No. of employees `00016.80.8 2,233.0%   
Total wages/salary Rs m28,4951,801 1,582.0%   
Avg. sales/employee Rs Th10,418.310,748.9 96.9%   
Avg. wages/employee Rs Th1,697.02,395.2 70.8%   
Avg. net profit/employee Rs Th1,523.02,641.1 57.7%   
INCOME DATA
Net Sales Rs m174,9438,083 2,164.3%  
Other income Rs m1,065829 128.4%   
Total revenues Rs m176,0088,913 1,974.8%   
Gross profit Rs m44,931234 19,185.1%  
Depreciation Rs m9,12237 24,856.4%   
Interest Rs m1,5252 84,738.9%   
Profit before tax Rs m35,3491,025 3,448.3%   
Minority Interest Rs m-720-   
Prior Period Items Rs m8317 494.0%   
Extraordinary Inc (Exp) Rs m01,696 0.0%   
Tax Rs m9,785752 1,301.2%   
Profit after tax Rs m25,5751,986 1,287.7%  
Gross profit margin %25.72.9 886.4%  
Effective tax rate %27.773.4 37.7%   
Net profit margin %14.624.6 59.5%  
BALANCE SHEET DATA
Current assets Rs m119,54212,678 942.9%   
Current liabilities Rs m61,2062,433 2,515.7%   
Net working cap to sales %33.3126.7 26.3%  
Current ratio x2.05.2 37.5%  
Inventory Days Days7633 232.4%  
Debtors Days Days9022 399.6%  
Net fixed assets Rs m131,66069 190,260.0%   
Share capital Rs m903160 565.2%   
"Free" reserves Rs m134,07311,460 1,169.9%   
Net worth Rs m134,97611,621 1,161.5%   
Long term debt Rs m56,4780-   
Total assets Rs m266,07314,400 1,847.8%  
Interest coverage x24.2570.5 4.2%   
Debt to equity ratio x0.40-  
Sales to assets ratio x0.70.6 117.1%   
Return on assets %10.213.8 73.8%  
Return on equity %18.917.1 110.9%  
Return on capital %19.323.6 81.7%  
Exports to sales %00.7 0.0%   
Imports to sales %018.6 0.0%   
Exports (fob) Rs mNA60 0.0%   
Imports (cif) Rs mNA1,503 0.0%   
Fx inflow Rs m81,885186 43,953.1%   
Fx outflow Rs m21,5061,821 1,181.1%   
Net fx Rs m60,378-1,635 -3,694.0%   
CASH FLOW
From Operations Rs m41,1482,531 1,625.8%  
From Investments Rs m-25,287-8,270 305.8%  
From Financial Activity Rs m4,332-386 -1,123.1%  
Net Cashflow Rs m20,193-6,125 -329.7%  

Share Holding

Indian Promoters % 46.6 0.0 -  
Foreign collaborators % 0.2 75.0 0.3%  
Indian inst/Mut Fund % 11.3 2.0 565.0%  
FIIs % 31.9 1.6 1,993.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.1 21.5 47.0%  
Shareholders   98,259 41,647 235.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN LTD With:   FDC LTD.  UNICHEM LAB  DR. REDDYS LAB  AJANTA PHARMA  ALEMBIC LTD  

Compare LUPIN LTD With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty Close at Record Highs; Bank & Realty Stocks Rally(Closing)

After opening the day marginally higher, Indian share markets extended gains in the afternoon session after the government decided to cut tax rates on certain products and services.

Related Views on News

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

The ONLY Thing You Need to Know About Bitcoin(The 5 Minute Wrapup)

Jan 6, 2018

You either want it or you want to get as far away from it as possible - but Bitcoin is just the noise masking the REAL opportunity. Read about it here...

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN LTD SHARE PRICE


Jan 19, 2018 (Close)

TRACK LUPIN LTD

  • Track your investment in LUPIN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

LUPIN LTD - NATCO PHARMA COMPARISON

COMPARE LUPIN LTD WITH

MARKET STATS